Alzheimer's disease treatment
An investigational new drug targeting amyloid and tau which is known as the protein that causes Alzheimer's disease
Abnormal amyloid beta plaques and tau tangles are known to be the main causes of hypomnesia and cognitive decline. BEY2153 is a ground-breaking investigational new drug that blocks both amyloid and tau.
An efficacy study performed on animal and cellular models with Alzheimer’s disease showed that the drug enhances cognitive and behavioral functions and inhibits neuronal death. In particular, BEY2153 is expected to have a high efficacy at a low dose with its permeability through the blood brain barrier. Also, unwanted effects with a high dose can be avoided.
Our research team is currently in non-clinical (GLP) study of BEY2153 and aims to enter into clinical trial in 2019.